TrialBMC urology2020

Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE).

Andrea Necchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.